These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 35078116)

  • 21. Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanel.
    Trigg A; Brohan E; Cocks K; Jones A; Tahami Monfared AA; Chabot I; Meier G; Campbell R; Li H; Ngo LY
    Epilepsy Behav; 2021 May; 118():107938. PubMed ID: 33839450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
    Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM).
    Husni RE; Ngo LY; Senokuchi H; Patten A; Hiramatsu H; Watanabe K; Yamamoto T
    Epilepsia Open; 2022 Mar; 7(1):59-66. PubMed ID: 34657389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.
    Kwan P; Mintzer S; Laurenza A; Patten A; Cartwright K
    Epilepsy Behav Case Rep; 2018; 9():1-5. PubMed ID: 29707476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study.
    Punia V; Klein P; Mihaylova T; Biton V; Samad O; Ngo LY; Kumar D; Malhotra M
    J Neurol; 2024 Jul; 271(7):4587-4598. PubMed ID: 38730096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study.
    Gao L; Lu Q; Wang Z; Yue W; Wang G; Shao X; Guo Y; Yi Y; Hong Z; Jiang Y; Xiao B; Cui G; Gao F; Hu J; Liang J; Zhang M; Wang Y
    Front Neurol; 2023; 14():1236046. PubMed ID: 37712083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study).
    Yamamoto T; Lim SC; Ninomiya H; Kubota Y; Shin WC; Kim DW; Shin DJ; Hoshida T; Iida K; Ochiai T; Matsunaga R; Higashiyama H; Hiramatsu H; Kim JH
    Epilepsia Open; 2020 Jun; 5(2):274-284. PubMed ID: 32524053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
    Plosker GL
    CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
    Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.